Longevity & Anti-Aging
NAD+, peptide protocols, biomarker testing, and proactive healthspan programs.
About this treatment area
Longevity clinics take a preventive, data-driven approach: extensive biomarker testing, epigenetic age assessment, and protocols aimed at extending healthspan rather than treating disease. NAD+ infusions, mitochondrial peptides, and senolytic strategies are common. Evidence quality varies widely — the best clinics are transparent about what’s proven versus promising.
Relevant peptides
Regulatory status as of September 2026. Always confirm with your provider.
NAD+
Compoundable
Coenzyme for cellular energy. IV infusion or subcutaneous. Real but modest evidence base.
Epitalon
Research only
Pineal peptide studied for telomerase activation. Russian research, limited Western trials.
MOTS-c
Research only
Mitochondrial-derived peptide. No completed human trials. WADA-banned since 2024.
SS-31
FDA-approved
Elamipretide. FDA-approved for Barth syndrome only. Longevity use is off-label/gray.
Thymosin Alpha-1
Compoundable
Immune-modulating peptide. Approved in 35+ countries, not US. Compounding status changing.
GHK-Cu
Compoundable
Copper peptide. Well-established topically for skin. Injectable use is unapproved.